Objective: To evaluate effectiveness of MiniMed™ AHCL on outcomes of study participants with different glycemic management challenges.

Methods: Adults (N=128, ≥18 years) with T1D from 16 investigational sites, underwent baseline run-in (~2wks) of continuous subcutaneous insulin infusion (CSII), sensor-augmented pump (SAP) or HCL therapy, followed by study period (3 months) with MiniMed™ AHCL. In this exploratory analysis, participants with different baseline glycemic characteristics (mean SG and SD of SG) were identified using Hierarchical Clustering Analysis with Ward’s method and stratified into 5 cohorts. AHCL glycemic outcomes were evaluated and compared to run-in outcomes.

Results: After AHCL initiation, overall glycemic control improved regardless of baseline glycemic characteristics (i.e., low-to-high mean SG and SD of SG) (Table). As expected, those from Cluster 5 with highest baseline mean SG and SD of SG improved the most. While those from Cluster 1 with lowest baseline mean SG and SD of SG achieved the highest TIR. Although those from Cluster 2 achieved better glycemic outcomes compared to their baseline, they didn’t outperform those from Cluster 3, possibly due to their higher SD of SG and less aggressive carb ratio.

Conclusion: Improved glycemic control was observed with MiniMed™ AHCL regardless of glycemic conditions at baseline.


J.Shin: Employee; Medtronic. Z.Dai: Employee; Medtronic. F.Niu: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.